Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

623 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis.
Ripa M, Rodríguez-Núñez O, Cardozo C, Naharro-Abellán A, Almela M, Marco F, Morata L, De La Calle C, Del Rio A, Garcia-Vidal C, Ortega MDM, Guerrero-León MLA, Feher C, Torres B, Puerta-Alcalde P, Mensa J, Soriano A, Martínez JA. Ripa M, et al. Among authors: torres b. J Antimicrob Chemother. 2017 Dec 1;72(12):3443-3452. doi: 10.1093/jac/dkx315. J Antimicrob Chemother. 2017. PMID: 28961801
A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; RALPEP Study Group. Leal L, et al. Among authors: torres b. J Antimicrob Chemother. 2016 Jul;71(7):1987-93. doi: 10.1093/jac/dkw049. Epub 2016 Mar 18. J Antimicrob Chemother. 2016. PMID: 26994089 Clinical Trial.
A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; MARAVIPEP Study Group. Leal L, et al. Among authors: torres b. J Antimicrob Chemother. 2016 Jul;71(7):1982-6. doi: 10.1093/jac/dkw048. Epub 2016 Mar 18. J Antimicrob Chemother. 2016. PMID: 26994091 Clinical Trial.
Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.
Rojas J, Blanco JL, Marcos MA, Lonca M, Tricas A, Moreno L, Gonzalez-Cordon A, Torres B, Mallolas J, Garcia F, Gatell JM, Martinez E. Rojas J, et al. Among authors: torres b. J Antimicrob Chemother. 2016 Jul;71(7):1975-81. doi: 10.1093/jac/dkw078. Epub 2016 Mar 28. J Antimicrob Chemother. 2016. PMID: 27021341 Free article.
Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Inciarte A, Leal L, González E, León A, Lucero C, Mallolas J, Torres B, Laguno M, Rojas J, Martínez-Rebollar M, González-Cordón A, Cruceta A, Arnaiz JA, Gatell JM, García F; STRIBPEP Study Group. Inciarte A, et al. Among authors: torres b. J Antimicrob Chemother. 2017 Oct 1;72(10):2857-2861. doi: 10.1093/jac/dkx246. J Antimicrob Chemother. 2017. PMID: 29091217 Clinical Trial.
Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis-authors' response.
Ripa M, Rodríguez-Nuñez O, Cardozo C, Naharro-Abellán A, Almela M, Marco F, Morata L, De La Calle C, Del Río A, Garcia-Vidal C, Ortega MDM, Guerrero-León MLA, Fehér C, Torres B, Puerta-Alcalde P, Mensa J, Soriano A, Martínez JA. Ripa M, et al. Among authors: torres b. J Antimicrob Chemother. 2018 Jun 1;73(6):1732-1733. doi: 10.1093/jac/dky063. J Antimicrob Chemother. 2018. PMID: 29506238 No abstract available.
Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019.
Garcia-Vidal C, Moreno-García E, Hernández-Meneses M, Puerta-Alcalde P, Chumbita M, Garcia-Pouton N, Linares L, Rico V, Cardozo C, Martínez JA, García F, Mensa J, Castro P, Nicolás JM, Muñoz J, Vidal D, Soriano A; COVID19-Researchers. Garcia-Vidal C, et al. Clin Infect Dis. 2022 Jan 7;74(1):127-132. doi: 10.1093/cid/ciaa964. Clin Infect Dis. 2022. PMID: 32649747 Free PMC article.
Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study.
Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, Fernandez-Pittol M, Pitart C, Inciarte A, Bodro M, Morata L, Ambrosioni J, Grafia I, Meira F, Macaya I, Cardozo C, Casals C, Tellez A, Castro P, Marco F, García F, Mensa J, Martínez JA, Soriano A; COVID-19 Researchers Group. Garcia-Vidal C, et al. Clin Microbiol Infect. 2021 Jan;27(1):83-88. doi: 10.1016/j.cmi.2020.07.041. Epub 2020 Jul 31. Clin Microbiol Infect. 2021. PMID: 32745596 Free PMC article.
623 results